Search

Your search keyword '"Anker, SD"' showing total 1,489 results

Search Constraints

Start Over You searched for: Author "Anker, SD" Remove constraint Author: "Anker, SD"
1,489 results on '"Anker, SD"'

Search Results

1. Request for regulatory guidance for cancer cachexia intervention trials

2. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)

3. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial

5. Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.

6. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

7. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

8. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial

9. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology

14. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines

15. Empagliflozin in heart failure with a preserved ejection fraction

16. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

18. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

19. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology

20. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

22. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial

23. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology

24. Cardiovascular and renal outcomes with empagliflozin in heart failure

25. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

26. The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial.

27. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

28. Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure

29. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology†

30. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial

31. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

32. Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future

33. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

34. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

35. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

36. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study

37. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

38. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis

39. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

41. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

42. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

43. Kommentar zu den ESC-Leitlinien zur Device-Therapie bei Herzinsuffizienz 2010

44. Biomarkers in kidney and heart disease

45. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction

47. ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

48. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients. results from the BACH Study (Biomarkers in ACute Heart Failure)

49. Why cachexia kills: Examining the causality of poor outcomes in wasting conditions

50. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

Catalog

Books, media, physical & digital resources